Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $17.0 million for the first quarter ended March 31, 2025. As a pre-revenue company, no product sales were reported for the quarter. The company's financial results reflect its continued investment in research and development for its clinical-stage pipeline.
Corbus reaffirmed its clinical development timelines for its key programs. Dose optimization and the determination of the Recommended Phase 2 Dose (RP2D) for the Nectin-4 targeting ADC CRB-701 remain on schedule for completion in the fourth quarter of 2025. This applies to its use in head and neck squamous cell carcinoma (HNSCC), cervical, and metastatic urothelial carcinoma (mUC) tumors.
The single ascending dose (SAD) and multiple ascending dose (MAD) study for the anti-obesity CB1 inverse agonist CRB-913 is on schedule for completion in the third quarter of 2025. Additionally, the dose escalation study for the anti-αvβ8 integrin monoclonal antibody CRB-601 in solid tumors is also on schedule for completion in the fourth quarter of 2025. These updates provide clarity on the anticipated progress of Corbus's pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.